Referred to the House Committee on Energy and Commerce.
This bill directs the Secretary of Health and Human Services to create a United States–Israel Bilateral Innovation for Research and Development in Health program (the BIRD Health Program) administered by the existing BIRD Foundation. The program is intended to fund and coordinate joint U.S.–Israeli projects in health technologies (medical devices, biologics, digital health, AI diagnostics, genomics, vaccines, telemedicine, infectious disease prevention, and related manufacturing and supply chain resilience).
Progressives emphasize equitable access, public-interest licensing, and strong data-privacy protections; conservatives emphasize protecting IP, U.S. jobs, and national-security/export-control safeguards.
Relative to its intended legislative type, this bill establishes a clearly stated, funded statutory authority to create and administer a U.S.-Israel bilateral health R&D program, including governance, program goals, funding authorization, and reporting requirements, but relies on high-level directions rather than detailed implementing rules for many operationally critical areas.
This bill directs the Secretary of Health and Human Services to create a United States–Israel Bilateral Innovation for Research and Development in Health program (the BIRD Health Program) administered by the existing BIRD Foundation.
The program is intended to fund and coordinate joint U.S.–Israeli projects in health technologies (medical devices, biologics, digital health, AI diagnostics, genomics, vaccines, telemedicine, infectious disease prevention, and related manufacturing and supply chain resilience).
It authorizes $10 million per year for fiscal years 2026–2032 (administration through the BIRD Foundation with oversight by HHS and Commerce), requires a program framework and reporting to Congress, and sets selection criteria emphasizing technical merit, commercial potential, bilateral partnership strength, and relevance to shared health priorities.
On substance the bill is modest, technocratic, and builds on an existing binational mechanism — features that improve prospects. However, it is only an authorization (not an appropriation), requires interagency and international coordination, and could attract objections tied to its bilateral focus or data-sharing provisions. Those factors, plus typical legislative process friction (committee consideration, floor scheduling, and separate appropriations), make it plausible but not certain to reach enactment.
Relative to its intended legislative type, this bill establishes a clearly stated, funded statutory authority to create and administer a U.S.-Israel bilateral health R&D program, including governance, program goals, funding authorization, and reporting requirements, but relies on high-level directions rather than detailed implementing rules for many operationally critical areas.
Progressives emphasize equitable access, public-interest licensing, and strong data-privacy protections; conservatives emphasize protecting IP, U.S. jobs, and national-security/export-control safeguards.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize equitable access, public-interest licensing, and strong data-privacy protections; conservatives emphasize protecting IP, U.S. jobs, and national-security/export-control safeguards.
A mainstream liberal/left-leaning observer would generally welcome a government-led program that supports biomedical R&D, infectious disease preparedness, vaccine development, and telemedicine—especially where public benefit and equitable access are explicit outcomes.
They would be sympathetic to strengthening supply chain resilience and to funding early-stage clinical trials and ecosystem support that could lead to cheaper, effective treatments.
However, they would be cautious that a program emphasizing commercialization and joint public–private projects could primarily benefit private firms and investors unless explicit safeguards ensure affordable access, fair pricing, and public-interest licensing.
A centrist/moderate observer would likely view the bill as a modest, pragmatic investment in allied bilateral cooperation that leverages an existing institution (the BIRD Foundation) to stimulate health innovation and grow commercial opportunities.
They would see the $10 million per year authorization as limited in size and therefore low fiscal risk, while noting potential benefits for supply chain resilience and commercialization of useful technologies.
Their perspective would focus on ensuring clear performance metrics, accountability, and that the program complements existing federal R&D efforts rather than duplicating them.
A mainstream conservative observer would weigh support for a U.S.–Israel partnership and innovation that could strengthen domestic manufacturing and national security against reservations about creating or expanding federal programs and ongoing appropriations.
They would view the modest authorized funding and use of the BIRD Foundation (a public–private model) more favorably than a large new federal bureaucracy, and they would appreciate emphasis on commercialization and supply chain resilience.
Major concerns would center on taxpayer subsidy of private firms, potential regulatory burdens, data-security and export-control implications, and ensuring that projects deliver U.S. economic benefits and protect IP.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On substance the bill is modest, technocratic, and builds on an existing binational mechanism — features that improve prospects. However, it is only an authorization (not an appropriation), requires interagency and international coordination, and could attract objections tied to its bilateral focus or data-sharing provisions. Those factors, plus typical legislative process friction (committee consideration, floor scheduling, and separate appropriations), make it plausible but not certain to reach enactment.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize equitable access, public-interest licensing, and strong data-privacy protections; conservatives emphasize protecting…
On substance the bill is modest, technocratic, and builds on an existing binational mechanism — features that improve prospects. However, i…
Relative to its intended legislative type, this bill establishes a clearly stated, funded statutory authority to create and administer a U.S.-Israel bilateral health R&D program, including governance, program goals, fun…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.